ERBB2 and breast cancer: The basal subtype of human breast cancer is typically triple-negative (estrogen receptor, progesterone receptor, and HER2/neu negative), and as a consequence has a poor prognosis, as it is most often poorly responsive to many of the current treatment strategies [27].